Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel
ALACHUA, Fla. and TAMPA, Fla., March 06, 2023 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Marc Began as Executive Vice President. Additionally, effective March 20, 2023, Mr. Began will be Axogen’s General Counsel, replacing Brad Ottinger, General Counsel and Chief Compliance Officer. As a member of the executive leadership team, Mr. Began will report directly to Karen Zaderej, Chairman, CEO and President, and will be responsible for all legal, business development, and compliance activities for Axogen.
Related news for (AXGN)
- Axogen Announces Chief Financial Officer Transition
- Axogen, Inc. Reports 2025 First Quarter Financial Results
- Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results
- Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
- axogen completes submission of biologics license application to u.s. food and drug administration for avance nerve graft®